Increasingly, cancer patients are traveling from the United States to China for chimeric antigen receptor T-cell (CAR-T) therapy, a personalized immunotherapy treatment. This trend highlights how US healthcare pricing and supply chain limitations have spurred medical tourism, as Chinese companies have industrialized CAR-T production, offering it at significantly lower costs and faster turnaround times than in the US. The development demonstrates the potential for other nations to capitalize on innovations originating elsewhere when accessibility is constrained, which may prompt further scrutiny of drug pricing models and manufacturing strategies within the biotechnology sector.
Read the full article at Futurism
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
